A
André D. Beaulieu
Researcher at Laval University
Publications - 66
Citations - 5606
André D. Beaulieu is an academic researcher from Laval University. The author has contributed to research in topics: Placebo & Osteoarthritis. The author has an hindex of 33, co-authored 66 publications receiving 5216 citations. Previous affiliations of André D. Beaulieu include University of British Columbia.
Papers
More filters
Journal ArticleDOI
Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study): a double-blind, placebo-controlled, randomised trial
Josef S Smolen,André D. Beaulieu,Andrea Rubbert-Roth,Cesar Ramos-Remus,Josef Rovensky,Emma Alecock,Thasia G. Woodworth,Rieke Alten +7 more
TL;DR: Tocilizumab could be an effective therapeutic approach in patients with moderate to severe active rheumatoid arthritis.
Journal ArticleDOI
Intraarticular injection of anakinra in osteoarthritis of the knee: a multicenter, randomized, double-blind, placebo-controlled study.
Xavier Chevalier,Philippe Goupille,André D. Beaulieu,F. X. Burch,William G. Bensen,Thierry Conrozier,Damien Loeuille,Alan Kivitz,David S. Silver,B. E. Appleton +9 more
TL;DR: Anakinra was well tolerated as a single 50-mg or 150-mg intraarticular injection in patients with OA of the knee, however, anakinRA was not associated with improvements in OA symptoms compared with placebo.
Journal ArticleDOI
Brodalumab, an Anti-IL17RA Monoclonal Antibody, in Psoriatic Arthritis
Philip J. Mease,Mark C. Genovese,Maria Greenwald,Christopher T. Ritchlin,André D. Beaulieu,A. A. Deodhar,Richard Newmark,Jing Yuan Feng,Ngozi Erondu,Ajay Nirula +9 more
TL;DR: Bdalumab significantly improved response rates among patients with psoriatic arthritis; responses were sustained through week 52 and larger studies of longer duration are necessary to assess adverse events.
Journal ArticleDOI
Effect of interleukin-6 receptor blockade on surrogates of vascular risk in rheumatoid arthritis: MEASURE, a randomised, placebo-controlled study
Iain B. McInnes,Liz Thompson,Jon T. Giles,Joan M. Bathon,Jane E. Salmon,André D. Beaulieu,Christine E Codding,Timothy H Carlson,Christian Delles,Janet S. Lee,Naveed Sattar +10 more
TL;DR: These data provide the first detailed evidence for the modulation of lipoprotein particles and other surrogates of vascular risk with IL-6R inhibition and favourably modified most, but not all, measured vascular risk surrogates.
Journal ArticleDOI
Adalimumab significantly reduces both spinal and sacroiliac joint inflammation in patients with ankylosing spondylitis: a multicenter, randomized, double-blind, placebo-controlled study.
Robert G. W. Lambert,David Salonen,Proton Rahman,Robert D. Inman,Robert L. Wong,Steven G Einstein,Glen T. D. Thomson,André D. Beaulieu,Denis Choquette,Walter P. Maksymowych +9 more
TL;DR: Adalimumab significantly reduced both spinal and SI joint inflammation in patients with active ankylosing spondylitis after 12 weeks of treatment, and these improvements were maintained for up to 52 weeks.